RSS   Newsletter   Contact   Advertise with us
Post Online Media

Concordia CEO Mark L. Thompson to step down

ConcordiaConcordia International, a specialty pharmaceutical company, announced that Mark L. Thompson will step down as chief executive officer following the appointment of a successor.
Article continues below

READ MORE Mark Thompson new CEO of The New York Times Company

Mr. Thompson is the Founder, a Director, Chairman and Chief Executive Officer of Concordia International Corp. He was Senior Vice President and General Counsel of Legacy Pharma Limited Partnership, co-founder of Trimel Pharmaceuticals and Tribute Pharmaceuticals Inc.

From 2001 to 2005, Mr. Thompson was employed by Biovail Corporation (currently Valeant), where he held the title of Vice-President, Business Development and, before that, Associate General Counsel.

Prior to joining Biovail, Mr. Thompson was an associate at Osler, Hoskin and Harcourt LLP.

Mr. Thompson holds an H.B.A., and M.A. from York University and an L.L.B. from the University of Ottawa.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy